Funded Startups in Basel
Across the 43 Basel-area entries, the largest disclosed round is Windward Bio’s $165M (2026-05-04, Series B).
Across the 43 Basel-area entries, the largest disclosed round is Windward Bio’s $165M (2026-05-04, Series B). That figure dwarfs the next-largest disclosed amounts visible here—$147M for Noema Pharma (2024-12-11, Series B) and $125M for VectivBio (2022-10-13, Post-IPO Equity)—while several recent rounds sit below $10M (e.g., Moonlight AI at $3M on 2026-05-06; Scailyte at $2M on 2023-12-04). Timing is also clustered: the list spans 2020-04-22 (FoRx Therapeutics, $10M) through 2026-06-11 (ClearideBio Therapeutics, undisclosed), and the most recent 12 months concentrate multiple large events, including Granite Bio’s $70M (2025-04-24, Series B) and Nuclidium’s $34M (2026-05-28, Series B). Sector-wise, biotechnology is the dominant theme (appearing in 24 of 43 rows), and “Series Unknown” or blank deal stages are common: “Series Unknown” appears 10 times and “undisclosed” amounts appear 3 times.
Most recent rounds
43 shownRelated listings
Frequently asked
What stands out on deal size in Basel, and how extreme is it versus the rest of the disclosed rounds?
Windward Bio’s $165M (2026-05-04, Series B) is the only disclosed round above $100M in this list. The next tier is much lower—Noema Pharma at $147M (2024-12-11) and VectivBio at $125M (2022-10-13)—while several entries cluster in the single-digit millions (e.g., Axom $880K on 2023-06-05; Scailyte $2M on 2023-12-04).
Is there a recent-time cluster in Basel’s most recent rounds, or are they evenly spread from 2020 to 2026?
Rounds span from 2020-04-22 (FoRx Therapeutics, $10M) to 2026-06-11 (ClearideBio Therapeutics, undisclosed), but the densest activity in the excerpt is concentrated in 2026, with multiple entries in May 2026 (Hephaistos 2026-06-01 at $190K; Nuclidium 2026-05-28 at $34M; Windward Bio 2026-05-04 at $165M).
How dominant is biotechnology relative to other sectors in this Basel list?
Biotechnology appears in 24 of 43 rows, making it the clear lead sector compared with other categories that occur fewer times (for example, Health Care appears in several rows such as Nuclidium and Axom, but not at the same frequency as biotech). The largest disclosed rounds also align with biotech entries: Windward Bio ($165M, 2026-05-04) and Granite Bio ($70M, 2025-04-24).
What stage labels are most common, and do they indicate missing or non-standard disclosures?
“Series Unknown” is the most frequent stage label at 10 entries, and 3 rows show “undisclosed” amounts (ClearideBio Therapeutics on 2026-06-11; BioTara on 2024-09-11; FimmCyte on 2023-09-05). Several large disclosed financings still have explicit stages (e.g., Nuclidium’s Series B $34M on 2026-05-28; Granite Bio’s Series B $70M on 2025-04-24), but stage ambiguity is a recurring pattern.
Are there notable outliers beyond sheer size, such as unusual financing types?
Yes. The list includes multiple debt/private-capital labeled rounds that are much smaller than the equity-dominant outliers: FGen $100K debt financing (2021-12-12) and MaxWell Biosystems $100K debt financing (2021-12-10). By contrast, large equity-style rounds include VectivBio’s $125M Post-IPO Equity (2022-10-13) and Monte Rosa Therapeutics’ $95M Series C (2021-03-12).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.